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tological examination of the kidneys on day 7 revealed pro-S3226, a novel NHE3 inhibitor, attenuates ischemia-induced
nounced reduction of tubular necrosis, dilatation, protein castsacute renal failure in rats.
and cellular infiltration.Background. Acute renal failure (ARF) remains a major
Conclusions. These results demonstrate that an intravenousproblem in clinical nephrology characterized by sudden loss of
administration of S3226 acutely improves GFR and kidney func-the kidney function due to ischemia, trauma, and/or nephro-
tion and structure in both treated groups. In addition, in a sepa-toxic drugs. The current therapy of ARF is symptomatic with
rate set of studies S3226 significantly decreased post-occlusionmortality rates exceeding 50%. The aim of this study was to
renal pHi values. Thus, the inhibition of NHE3 with S3226investigate the effects of an intravenous infusion of S3226 (3-
may be beneficial in treatment of ischemic ARF.[2-(3-guanidino-2-methyl-3-oxopropenyl)-5-methyl-phenyl]-
N-isopropylidene-2-methyl-acrylamide dihydrochloride), a selec-
tive Na/H exchange subtype 3 (NHE3) blocker, in ischemia-
induced ARF in rats. In a second series of experiments cytosolic Acute renal failure (ARF) is a serious disease withpH (pHi) changes in the kidney during ARF were continuously
a patient mortality exceeding 50 percent. For decadesmeasured by means of nuclear magnetic resonance spectros-
therapeutic maneuvers have been symptomatic includingcopy (MRS).
Methods. ARF was induced by bilateral occlusion of renal mannitol, loop diuretics alone or in combination with do-
arteries for 40 minutes in three groups of anaesthetized Wistar pamine, dialysis and other supportive treatments [1, 2].
rats. Control rats (N 12) were infused with saline (6.25 mL/kg Apart from small-sized clinical studies examining atrialover 30 min) before occlusion and the compound groups (each
natriuretic peptides (ANP) in ARF that have demon-N  12) were infused with S3226 at a dose of 20 mg/kg over
strated improved creatinine clearance and reduced need30 minutes either before initiation of ischemia or immediately
after release of clamps. Plasma creatinine (PCr), creatinine clear- for dialysis, there is no treatment modality to date that
ance (CCr), urine volume, sodium, and potassium excretion were has provides a significant improvement of ARF [3].
determined up to seven days after release of clamps. In the Recently, several animal studies have indicated that dif-second series of experiments in anaesthetized rats the left kid-
ferent classes of chemical compounds ameliorate the out-ney was exposed by flank incision and fixed in a non-magnetic
come of ischemic and nephrotoxic ARF. It has been showndevice. An inflatable cuff was positioned around the pedicle
to induce ischemia without removing animals from the magnet. that ANP infusion has beneficial effects on norepineph-
A double-tuned 1H-31P home-built surface coil was placed above rine- and ischemia-induced ARF [4, 5]. Furthermore, it
the exposed kidney for the detection of pHi. has been demonstrated that xanthine derivatives such asResults. At day 1 after ischemia CCr in the control group was KW-3902 and CVT-124, which are adenosine A1-recep-significantly lower as compared to S3226-treated animals (con-
tor antagonists, significantly ameliorate cisplatin-, genta-trol 0.30  0.05 vs. before 0.90  0.26 and reperfusion 0.83 
0.15 mL/min/kg, respectively). PCr increased from 18 0.1mol/L micin- and ischemia-induced ARF in rats. As possible
before occlusion to 245 7mol/L in the control. The increase mechanisms of action, the natriuretic and renal hemody-
in PCr was significantly lower in the S3226 treated groups on namic effects of these compounds have been discussed asdays 1, 2, and 3 post-infusion. Fractional sodium excretion
beneficial principles in ARF [6, 7]. Furthermore, it hasdecreased significantly from 8.17% in the control to 1.42%
been demonstrated that an adenosine analog highly se-and 1.88% in the treated groups. Renal pHi was significantly
decreased by 0.15 units versus control during reperfusion. His- lective for A2A-receptors, the agonist DWH-146e, signif-
icantly ameliorated ischemia-induced ARF [8]. Moreover,
it has been suggested that endothelin may be involved inKey words: sodium-hydrogen-3 blocker, creatinine clearance, 31P-mag-
the pathophysiology of ischemic ARF. Elevated plasmanetic resonance spectroscopy, cytosolic pH, phosphate metabolism,
urinary excretion. levels of endothelin were reported in experimental and
human acute renal failure (abstract; Tomita et al, N EnglReceived for publication December 29, 2000
J Med 321:1127, 1989]. Since it has been shown that Na/and in revised form June 13, 2001
Accepted for publication July 13, 2001 H exchanger subtype 3 (NHE3) is involved in renal
ischemia-reperfusion injury, it could be postulated that a 2001 by the International Society of Nephrology
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Fig. 1. Effects of intravenous infusion of
S3226 in acute renal failure (ARF) on plasma
creatinine (A), blood urea nitrogen (BUN; B),
sodium (C) and potassium (D). Renal arteries
were occluded for 40 minutes. S3226 was in-
fused for 30 minutes before ischemia ( ; N 
12) or after release of clamps ( ; N  12) at
a dose of 20 mg/kg. Control rats received sa-
line in a volume of 6.25 mL/kg (; N  12).
Values are means  SEM, *P  0.05 vs. con-
trol group.
direct inhibition of this exchanger with a selective NHE3 Renal ischemia-reperfusion model
inhibitor could improve ARF [10]. The animals were randomly allocated to control and
Thus, the purpose of the present study was to examine two compound groups. During experiments the body
the effects of the NHE3 inhibitor S3226 in ischemia- temperature was kept constant (37C) by placing animals
induced ARF in rats [11]. In addition renal pHi changes on a heating pad. Rats were anaesthetized by Ketavet
in normoxic and ischemic kidney being treated with and Rompun at doses of 100 and 5 mg/kg i.m., respec-
S3226 were examined by means of nuclear magnetic res- tively. Kidneys were exposed through a flank incision
onance spectroscopy (MRS). We found that NHE3 inhi- and renal arteries and veins were clamped with artery
bition significantly improved the outcome of ARF in rats clamps for 40 minutes (Aesculap yasargil-clip, closing
and that this inhibition also reduced the renal pHi. force 0.98 to 1.28 N). Control rats received 0.9% NaCl
solution intravenously in a volume of 6.25 mL/kg body
weight for 30 minutes before occlusion. S3226 was dis-METHODS
solved in saline (20 mg/kg body weight) and infused in
Animals a volume of 6.25 mL/kg body weight before occlusion
Experiments were performed in male Wistar rats with for 30 minutes. The second compound group received
a mean body weight of 285  7.5 g. Animals were sup- S3226 (20 mg/kg for 30 min) immediately after release
plied by Aventis Tierhaltung and were kept in an air- of clamps. After termination of acute experiments rats
conditioned animal housing in a 12-hour light/dark cycle were monitored for seven days. On days 0, 1, 2, 3 and
at 22C and fed a standard diet (Altromin) and had 7 blood samples were collected retro-bulbary (in short
access to tap water ad libitum. All experiments were inhalation anesthesia) for determination of creatinine,
performed in accordance with the German Animal Pro- urea, sodium, potassium, and albumin. In addition, on
days 1 and 7 diuresis experiments were performed totection Law.
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Fig. 1. (Continued)
assess the excretory kidney function. Sodium and potas- kidney for signal detection. A thin copper foil was placed
between the kidney and the animal’s body to minimizesium in urine and plasma samples were measured by
flame photometry (Photometer Eppendorf, Hamburg, signal interferences originating in adjacent muscles and
skin tissue. 31P MRS measurements were performed atGermany), and creatinine and urea were determined
using the Crea plus and the Urica-quant method, re- 4.7 Tesla on a Biospec spectrometer (Bruker Medical,
Ettlingen, Germany). 31P NMR spectra exhibiting thespectively. The basis for selecting 20 mg/kg of S3226 was
its in vitro IC50 of 0.2 mol/L in fibroblasts transfected signals of ATP, phosphodiesters, inorganic and sugar
phosphates were collected at 81.1 MHz with 600 scans,with rat NHE3. The concentration measured in the intra-
vascular compartment after treatment was 2 mol/L and spectral width of 8000 Hz, data size of 512 points, pulse
width of 50, acquisition time of 0.028 s, and a recyclet1/2  30 minutes.
time of 0.4 s. With these parameters good quality spectra
Measurement of renal pHi by means of MRS were obtained within four minutes. As in kidney 31P
NMR spectra no phosphocreatine peak is visible, theSecond series of experiments. One week after unilat-
eral nephrectomy rats were anaesthetized with Inactin changes in chemical shift of the inorganic phosphate
(Pi) resonance, were related to the signal of an external(150 mg/kg, IP) and the remaining kidney was exposed
by flank incision and immobilized in a home-built device. standard (diphenylphosphonic acid contained in an adja-
cent capillary) to derive intracellular pHi. The pHi wasBody temperature was maintained constant (37C) with
a heating water pad. An inflatable cuff was positioned calculated according to the formula: pH 6.75 log(d
3.06)/(5.75  d), where d is the difference in chemicalaround the renal pedicle to induce ARF without remov-
ing the rat from the magnet. A double-tuned 1H-31P shift between the resonances of Pi and phosphocreatine
[12]. The compound S3226 was infused at the dose ofhome-built surface coil was placed above the exposed
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Table 1. Effects of drug treatment on urine output, urinary excretion of sodium potassium and albumin, glomerular filtration rate and
fractional excretion of sodium and potassium
S3226 before occlusion S3226 in reperfusion
Vehicle group 20 mg/kg per 30 min 20 mg/kg per 30 min
1 day a. t. 7 days a. t. 1 day a. t. 7 days a. t. 1 day a. t. 7 days a. t.
N12 N9 N12 N12 N12 N12
Urine output mL/kg 16.711.75 17.632.16 20.492.61 15.791.40 17.573.79 18.453.61
CCr mL/min/kg 0.300.05 3.220.37 0.900.26a 4.030.54 0.830.15a 4.571.07
UNaV mmol/kg 0.980.17 0.280.08 0.310.08a 0.570.13a 0.310.06a 0.450.11a
UKV mmol/kg 0.970.08 1.600.18 1.170.14 2.100.17 0.850.16 3.110.95
FENa % 8.171.30 0.210.06 1.420.45a 0.380.11 1.880.41a 0.350.09a
FEK % 198.6713.44 32.223.11 125.5523.41a 34.173.61 141.3123.71a 37.215.37
UAlbuminV mg/24 h — 0.420.03 — 0.290.04 — 0.330.06
Values are means  SEM. Abbreviations are: UNaV and UKV, sodium and potassium excretion rates; FENa and FEK, fractional excretion of sodium and potassium;
a. t., after treatment. Urine samples were collected by placing the rats in diuresis cages for 5 hours. S3226 was infused for 30 min before occlusion and after release
of clamps, respectively.
a P  0.05 to corresponding vehicle group value
20 mg/kg over 30 minutes before occlusion and a second mented CCr to 0.90 and 0.83 mL/min/kg on day 1 as
compared to controls (Table 1 and Fig. 1). Urine excre-time starting five minutes before release of clamps, re-
spectively. The rationale for two treatments was a phar- tion was not different between days 1 and 7.
The impairment of renal function also was reflectedmacokinetic study which revealed that only 10% of the
parent compound was renally excreted while the major by the changes in sodium and potassium concentration
in plasma and urine. Plasma sodium was markedly re-part of S3226 was metabolized in the liver. To achieve
a sufficient concentration of the compound at the renal duced in control and both compound groups on day 1
as compared to initial values. However, treatment withsite of action, in this series of experiments S3226 was
infused before and after induction of renal ischemia. the NHE3 blocker S3226 normalized the plasma sodium
concentration already at day 2. Plasma potassium con-
Histological evaluation centration was significantly increased in all groups on
day 1 in comparison with the initial values and was sig-For light microscopy all kidneys were removed in anes-
nificantly lower in the treated groups on days 2 and 3 asthesia on day 7 of reperfusion and fixed in 10% neutral
compared to the control group (Fig. 1 C, D). Urinarybuffered formalin and embedded in paraffin. Three to
sodium excretion was significantly reduced in the treated4 m sections were stained with hematoxylin and eosin
groups as compared to the control (0.31  0.08, 0.31 (H&E) or with periodic acid Schiff (PAS) stain.
0.06 vs. 0.98  0.17 mmol/kg body weight) on day 1
Statistical analysis (Table 1). In parallel fractional sodium excretion (FENa)
was 8.17% in the ischemic control versus 1.42% andValues are expressed as arithmetical mean  SEM.
1.88% in the treated groups on day 1 and decreasedA one-way ANOVA was calculated with SYSTAT for
further on day 7. Urinary potassium excretion was notWindows (SYSTAT, Inc., Evanston, IL, USA) followed
different on days 1 and 7, whereas FEK (fractional potas-by multiple pairwise comparisons according to Tukey.
sium excretion) was higher in the control group at day 1Null hypotheses were rejected at P  0.05.
as compared to the treated groups. FEK was not different
between groups at day 7 (Table 1). Urinary albumin
RESULTS excretion as a marker of glomerular lesions was mea-
After 40 minutes of bilateral renal artery occlusion sured on day 7 and revealed a slight reduction in the
treated groups as compared with the control group. Fur-and 24 hours of reperfusion, PCr (plasma creatinine) and
BUN significantly increased as compared to initial values thermore, in the control group 3 rats died on day 4,
whereas all animals survived in the treated groups, how-(P  0.05). On day 2 there was a further increase of PCr
and BUN which then gradually decreased on days 3 and ever, the difference was not statistically significant.
To assess renal pHi in ARF cytoplasmatic signals of7 (Fig. 1 A, B). In parallel, creatinine clearance (CCr)
dramatically decreased to 0.30 mL/min/kg body wt 24 Pi and other phosphate metabolites were measured by
NMR spectroscopy in vivo. Intravenous infusion ofhours after the release of occlusion as compared to our
routine laboratory values of 6 to 8 mL/min/kg in healthy S3226 according to protocol did not change the renal
pHi in sham operated rats as compared to vehicle controlrats. Infusion of S3226 in a dose of 20 mg/kg for 30
minutes prior to occlusion and after release of clamps (Fig. 2A). On the other hand, a 40 minute occlusion of
the renal artery caused a profound drop in pHi whichsignificantly reduced PCr and BUN and significantly aug-
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Fig. 2. Effect of S3226 on renal intracellular
pH of fasted uninephrectomized rats as moni-
tored by in vivo 31P NMR spectroscopy. The
drug was infused twice to maintain suitable
blood levels as indicated in the labeled boxes
at a dose of 20 mg/kg over 30 minutes. (A)
S3226 did not affect pHi during normoxia
(N  4 each group). (B) S3226 was infused
prior to and 5 minutes before ending of isch-
emia. In the S3226 group (N  8 for each
group) pHi was significantly reduced by 0.15
units (P 0.05) during the 5-hour reperfusion
period. Values are means  SEM. Symbols
are: () control, () drug. *P  0.05 vs. con-
trol group.
quickly recovered to the initial values as shown in rine- and ischemia-induced ARF [4, 5]. Glomerular fil-
tration rate (GFR), renal blood flow as well as urine andFigure 2B. However, after infusion of S3226 twice, before
sodium excretion were significantly improved in compar-occlusion and five minutes before release of clamps each
ison with vehicle groups. ANP has been shown to increasefor 30 minutes, the pHi remained significantly below the
GFR in pathophysiological states by altering pre- andpre-ischemic and vehicle values during the observation
post-glomerular vascular resistance resulting in enhance-time of five hours. At the same time there was a dramatic
ment of the glomerular capillary hydraulic pressure. Fur-reduction of renal adenosine 5-triphosphate (ATP) in
thermore, in a small sized study in ARF patients it wasthe ischemic period which recovered post-ischemically
shown that short-term parenteral infusion of ANP causedthough without reaching its pre-ischemic value (not
an increase in CCr and that the need for dialysis wasshown). There was no significant difference in ATP con-
significantly reduced [3].centration in the control versus drug group after induc-
S3226 is a potent NHE3 inhibitor in vitro, as showntion of ischemia.
in transfected fibroblasts [11]. In a micropuncture study,Histological examination of the kidneys on day 7 re-
microperfusion of proximal convoluted tubules withvealed pronounced reduction of tubular necrosis, dilata-
S3226 showed a dose-dependent 30% inhibition of fluidtion and protein casts, and cellular infiltration of the
and sodium absorption [16]. On the other hand, HOEbroadened peritubular interstitium in the treated groups
642, a selective NHE1 inhibitor, did not alter fluid and(Fig. 3B) as compared to the vehicle group (Fig. 3A).
sodium absorption in proximal convoluted tubules. As
the luminal Na/H exchanger NHE3 plays a prominent
DISCUSSION role in proximal fluid and sodium reabsorption, its contri-
Intravenous infusion of the NHE3 inhibitor S3226 bution was assessed by micropuncture in NHE3 knock-
prior to renal artery occlusion and in reperfusion dramat- out mice. It was demonstrated that proximal fluid reab-
ically improved the outcome of ARF in rats. There was sorption was blunted in this species indicating that NHE3
a significant reduction of plasma creatinine and BUN is the major NHE isoform mediating sodium and fluid
concentration and a modest but significant increase of transport in the proximal tubule [17, 18]. In our experi-
CCr 24 hours after administration of S3226. In the past, ments ischemic ARF caused FENa of 8.17%, which was
several experimental studies have demonstrated that it significantly reduced to 1.42 and 1.88% after administra-
was possible to improve the course of ischemic ARF tion of S3226 in both treated groups. This indicates that
by using agents such as atrial natriuretic factor (ANF), administration of S3226 improves tubular function and
adenosine A1 antagonist and A2 agonists, endothelin ETA recovery already at day 1. In parallel, the diminished
antagonists, as well as the nitric oxide (NO) donor FK409 plasma sodium concentration was restored to normal.
[4–6, 8, 14–16]. Atrial natriuretic peptide (ANP) has been At the same time plasma potassium and FEK were sig-
nificantly decreased as compared to vehicle control indi-shown to reverse experimental models of norepineph-
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during infusion of S3226. During an observation time of
five hours (reperfusion period) the renal pHi was signifi-
cantly lower in the treated group as compared to the
vehicle group. This delayed restoration of pHi as a result
of NHE3 inhibition prevents the cell from sodium load.
In the post-acute phase it has been shown by Wang
et al. that 30 minutes of renal artery occlusion caused
approximately 70% decrease in NHE3 mRNA and NHE3
activity, resulting in overexpression of colonic type H/
K-ATPase in the cortex to compensate the reabsorp-
tion of increased bicarbonate load resulting from sup-
pression of NHE3 [10]. However, the activity of re-
maining NHE3 transporters may be increased by the
cytosolic acidification that occurs in the occlusion phase
and in addition, reperfusion could activate NHE3 again.
Thus, inhibiting NHE3 may improve the outcome of
ARF. On the other hand, it has been demonstrated that
metabolic acidosis caused increased expression of renal
brush border NHE3 protein resulting in normalization
of pHi during metabolic acidosis [20–22]. Therefore, a
sustained cellular acidosis could accelerate recovery of
the cell function.
In the present study, the S3226 treated groups revealed
pronounced reduction of tubular necrosis and cellular
infiltration as well as survival of all rats in this groups
as compared to the vehicle group (3 rats out of 12 died
before termination of the experiment), however the dif-
ference was not statistically significant. A distinct preser-
vation of the normal tubular architecture was also shown
by others employing the platelet-activating factor (PAF)Fig. 3. Overview of the kidney cortex from a control (A) and a treated
antagonist Ro-244736, the spontaneous NO donor FK-(B) rat. In panel A, tubular single or group necrosis (often extruded
into the lumen), tubular dilation and diffusely distributed round cell 406, and the selective A2A-adenosine receptor agonist
infiltration in a broadened interstitium are visible, but these lesions are DWH-146e, [8, 15]. PAF is vasoconstrictive and promotesnot observed in panel B. PAS staining, magnification 	160.
platelet aggregation and its role in leukocyte-endothelial
adhesion and leukocyte extravasation following reperfu-
sion was postulated. Moreover, it has been demonstrated
that oral administration of losartan, an angiotensin II re-cating that NHE3 inhibition may contribute to restora-
tion of the proximal tubular transport process. ceptor subtype 1 antagonist was able to improve the out-
come of ischemic ARF by reducing plasma creatinine,Recently, a great body of evidence has accumulated
implicating endothelin peptides (ET) in pathophysiology and proteinuria and increasing the survival rate [ab-
stract; Heller et al, Kidney Int 55(Suppl):S113, 1996].of ARF. The vasoconstrictor properties of ET not only
affect vascular tone, but also influence tubular sodium and This effect is likely linked to NHE3 activity since pre-
vious observations demonstrated that intrarenal angio-water transport [19]. It has been demonstrated that the
selective ETA receptor blockers LU-135252 and BQ-123 tensin II (Ang II) dose-dependently regulates the lu-
minal NHE3 possibly by protein kinase C stimulationpossess beneficial effects in ischemic ARF due to in-
creased renal perfusion and attenuation of intracellular and a reduction of cAMP production [23].
On the other hand, adenosine receptors are knowncalcium accumulation in the early phase of ischemic ARF
[13, 14]. modulators of renal haemodynamics and potent inhibi-
tors of inflammation. It has been reported that adenosineCytosolic [Ca2], [H], and [Na] are closely linked
to NHE3 activity. The increased sodium load would lead A1-receptor antagonists reduce renal injury in models of
ARF by decreasing adenosine-mediated vasoconstric-under conditions of reduced ATP supply during ischemia
to a reversed action of Na/Ca2 exchanger resulting in tion of afferent arterioles [6, 7]. In addition, the pro-
nounced diuretic effect of these compounds was attrib-an increased intracellular calcium with its detrimental
effects. Therefore, in a second series of experiments we uted to their interaction with the NHE3 via cAMP
accumulation. Another interesting compound, whichevaluated changes in renal pHi with the MRS technique
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nephrine-induced acute renal failure: Beneficial effects of atrialwas shown to improve markedly the outcome of ischemic
natriuretic factor. Nephron 44:240–244, 1986
ARF, is the adenosine A2A-receptor agonist DWH-146e. 5. Conger JD, Falk SA, Yuan BH, Schrier RW: Atrial natriuretic
peptide and dopamine in a rat model of ischemic acute renal failure.This compound was infused via minipumps following
Kidney Int 35:1126–1132, 1989release of clamp causing a significant reduction of plasma
6. Yao K, Kusaka H, Sano J, et al: Diuretic effects of KW-3902, a
creatinine, inhibition of inflammation and increase in novel adenosine A1-receptor antagonist, in various models of acute
renal failure in rats. Jpn J Pharmacol 64:281–288, 1994urine osmolality [8].
7. Gellai M, Schreiner GF, Ruffolo RR Jr, et al: CVT-124, a novelIn summary, the present results demonstrate that adenosine A1 receptor antagonist with unique diuretic activity.
S3226, a selective NHE3 inhibitor, exerts protective ef- J Pharmacol Exp Ther 286:1191–1196, 1998
8. Okusa MD, Linden J, Macdonald T, Huang L: Selective A2Afects on kidney function and structure during ischemic
adenosine receptor activation reduces ischemia-reperfusion injuryARF. These effects achieved in two sets of studies in- in rat kidney. Am J Physiol 277:F404–F412, 1999
clude amelioration of GFR, FENa and FEK, as well as a 9. Shibouta Y, Suzuki N, Shino A, et al: Pathophysiological role of
endothelin in acute renal failure. Life Sci 46:1611–1618, 1990decrease in renal pHi. The demonstrated pharmacologi-
10. Wang Z, Rabb H, Craig T, et al: Ischemic-reperfusion injury incal effects are obviously the cause for reduced cellular the kidney: overexpression of colonic H-K-ATPase and suppres-
sion of NHE-3. Kidney Int 51:1106–1115, 1997necrosis in proximal tubules. The observed interstitial
11. Schwark JR, Jansen HW, Lang HJ, et al: S3226, a novel inhibitorreparative processes in treated rats are in contrast to
of Na/H exchanger subtype 3 in various cell types. Pflu¨gers Arch
those in the untreated animals in which the full recovery 436:797–800, 1998
12. Reichel H, Humburger F, Juretschke HP, Ritz E: Renal 31-of the kidney function is uncertain because of the more
phosphorus-magnetic resonance spectral changes in experimentalor less diffuse degeneration status at day 7. No mortality uremia. Nephron 73:27–33, 1996
in the treated rats but decreased survival rate in the 13. Birck R, Knoll T, Braun C, et al: Improvement of postischemic
acute renal failure with the novel orally active endothelin-A recep-untreated rats corresponds to the observed histological
tor antagonist LU 135252 in the rat. J Cardiovasc Pharmacol 32:findings. Thus, the inhibition of NHE3 with S3226 may 80–86, 1998
14. Mino N, Kobayashi M, Nakajima A, et al: Protective effect of abe beneficial in treatment of ischemic ARF.
selective endothelin receptor antagonist, BQ-123, in ischemic acute
renal failure in rats. Eur J Pharmacol 221:77–83, 1992
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